Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 7/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075444 | 0.89 | HCRTR2 (0.56) | HCRTR2MAPTTP53KEAP1NFE2L2 | |
| SCHEMBL1040417 | 0.89 | HCRTR2 (0.55) | HTTHCRTR2MAPTKEAP1NFE2L2 | |
| SCHEMBL1036906 | 0.85 | HCRTR2 (0.65) | HTTHCRTR2ESR1KMT2AMEN1 | |
| SCHEMBL1038651 | 0.83 | L3MBTL1 (0.47) | HTTHCRTR2ESR1KMT2AMEN1 | |
| SCHEMBL1039256 | 0.80 | HCRTR2 (0.51) | HCRTR2MAPTKEAP1NFE2L2 | |
| SCHEMBL1035759 | 0.79 | ESR1 (0.50) | HCRTR2ESR1KMT2AMEN1TP53 | |
| SCHEMBL21033410 | 0.74 | HPGD (0.51) | HCRTR2MAPTPOLBKEAP1NFE2L2 | |
| SCHEMBL1040787 | 0.74 | NPSR1 (0.46) | HCRTR2TP53LMNA | |
| SCHEMBL1035896 | 0.74 | KEAP1 (0.44) | HTTHCRTR2ESR1KMT2AMEN1 | |
| SCHEMBL1039041 | 0.73 | HCRTR2 (0.77) | HCRTR2MAPTTP53KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | HCRTR2, HCRTR1, GIPR | HTT 209/4885HCRTR2 1/4885ESR1 702/4885 |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | HCRTR2, HCRTR1, GIPR | HTT 209/4885HCRTR2 1/4885ESR1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.